Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
SOLID COMPOSITIONS
FIELD OF THE INVENTION
The present invention relates to solid compositions comprising anti-HCV
compounds and methods of using the same to treat HCV infection.
BACKGROUND
The hepatitis C virus (HCV) is an RNA virus belonging to the Hepacivirus genus
in
the Flaviviridae family. The enveloped HCV virion contains a positive stranded
RNA genome
encoding all known virus-specific proteins in a single, uninterrupted, open
reading frame. The
open reading frame comprises approximately 9500 nucleotides and encodes a
single large
polyprotein of about 3000 amino acids. The polyprotein comprises a core
protein, envelope
proteins El and E2, a membrane bound protein p7, and the non-structural
proteins NS2, NS3,
NS4A, NS4B, NS5A and NS5B.
HCV infection is associated with progressive liver pathology, including
cirrhosis and
hepatocellular carcinoma. Chronic hepatitis C may be treated with
peginterferon-alpha in
combination with ribavirin. Substantial limitations to efficacy and
tolerability remain as many
users suffer from side effects, and viral elimination from the body is often
inadequate.
Therefore, there is a need for new drugs to treat HCV infection.
SUMMARY OF THE INVENTION
The present invention features solid compositions comprising a HCV inhibiting
compound or a pharmaceutically acceptable salt thereof, wherein said HCV
inhibiting compound
is selected from the group consisting of:
dimethyl (2S ,2'S)-1,1 ' -((2S ,2 ' S)-2,2 '-(4,4 ' -((2S ,5S)-1-(4-
tert-butylphenyl)pyrrolidine-
2,5-diy1)bis(4,1-phenyl ene))bis(azanediy1)bis(oxomethylene)bis(pyrrol idine-
2,1-diy1))bis(3-
1
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
110 H
HQ(r111 N = NrN
E\11
methyl-1 -oxobutane-2, 1 -diy1)dicarbamate ( ,0511
hereinafter Compound IA),
methyl [(2S)- 1- { (2 S)-2- [4-(4- {5-(4- {2- [(2 S)- 1- { (2 S)-2-
[(methoxycarbonyl)amino] -3 -
methylbutanoyl} pyrrolidin-2-y1]- 1 H-imidazol-4-y1} pheny1)- 1 -[6-(piperidin-
1 -yl)pyridin-3 -y1]-
.. 1 H-pyrrol-2-y1} phenyl)- 1 H-imidazo 1-2-yl]pyrro lidin- 1-y1} -3 -methyl-
1 -oxobutan-2-yl]carbamate
NH
, hereinafter Compound IB),
methyl { (2S,3R)- 1- [(25)-2- { 6- [(2R,5R)- 1 -(4-tert-butylpheny1)-5 -(2- {
(2S)- 1- [N-
(methoxycarbony1)-0-methyl-L-threonyl]pyrrolidin-2-y1} -1H-benzimidazol-6-
yl)pyrrolidin-2-
y1]-1H-benzimidazol-2-y1} pyrro lidin- 1 -y1]-3 -methoxy- 1 -oxobutan-2-y1}
carbamate
H
H
HN \C) )-NH
( c)\ , hereinafter Compound Ic), and
methyl { (2 S)- 1- [(2S)-2- {5 -[(2R,5R)- 1- [2,5 -difluoro-4-
(trifluoromethyl)phenyl] -5- {2-
[(2S)- 1- { (2 S)-2-[(methoxyc arbonyl)amino] -3 -methylbutanoyl} pyrro lidin-
2-yl] -1 H-
b enzimidazol-5 -y1} pyrro lidin-2-yl] - 1 H-b enzimidazol-2-y1} pyrrolidin- 1
-y1]-3 -methyl- 1 -
F F F
= r)1
N N0
oxobutan-2-y1} carbamate (-1\10S-C)\ hereinafter Compound
ID).
2
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
Compound IA, IB, Ic and ID are potent HCV inhibitors. The solid compositions
of the
invention comprise (1) a compound selected from Compound IA, IB, Ic or ID, or
a
pharmaceutically acceptable salt thereof, in an amorphous form, (2) a
pharmaceutically
acceptable hydrophilic polymer, and optionally (3) a pharmaceutically
acceptable surfactant.
In one aspect, the present invention features a solid composition comprising a
solid
dispersion, wherein the solid dispersion comprises (1) a compound selected
from Compound IA,
IB, Ic or ID (or a pharmaceutically acceptable salt thereof) in an amorphous
form, (2) a
pharmaceutically acceptable hydrophilic polymer, and (3) a pharmaceutically
acceptable
surfactant. The surfactant can be, without limitation, either formulated in
the solid dispersion or
separately combined or mixed with the solid dispersion. Preferably, the
hydrophilic polymer has
a Tg of at least 50 C. More preferably, the hydrophilic polymer has a Tg of
at least 80 C.
Highly preferably, the hydrophilic polymer has a Tg of at least 100 C. Also
preferably, the
surfactant has a HLB value of at least 10. Hydrophilic polymers with Tgs of
below 50 C, such
as a polymer having a Tg of at least 25 C, and/or surfactants having HLB
values of below 10,
can also be used.
In one embodiment of this aspect of the invention, the hydrophilic polymer is
selected
from homopolymer of N-vinyl lactam, copolymer of N-vinyl lactam, cellulose
ester, cellulose
ether, polyalkylene oxide, polyacrylate, polymethacrylate, polyacrylamide,
polyvinyl alcohol,
vinyl acetate polymer, oligosaccharide, or polysaccharide. Non-limiting
examples of suitable
hydrophilic polymers include homopolymer of N-vinyl pyrrolidone, copolymer of
N-vinyl
pyrrolidone, copolymer of N-vinyl pyrrolidone and vinyl acetate, copolymer of
N-vinyl
pyrrolidone and vinyl propionate, graft copolymer of polyethylene
glycol/polyvinyl
caprolactam/polyvinyl acetate (e.g., Soluplus), polyvinylpyrrolidone,
methylcellulose,
ethylcellulose, hydroxyalkylcelluloses, hydroxypropylcellulose,
hydroxyalkylalkylcellulose,
hydroxypropylmethylcellulose, cellulose phthalate, cellulose succinate,
cellulose acetate
phthalate, hydroxypropylmethylcellulose phthalate,
hydroxypropylmethylcellulose succinate,
hydroxypropylmethylcellulose acetate succinate, polyethylene oxide,
polypropylene oxide,
copolymer of ethylene oxide and propylene oxide, methacrylic acid/ethyl
acrylate copolymer,
methacrylic acid/methyl methacrylate copolymer, butyl methacrylate/2-
dimethylaminoethyl
methacrylate copolymer, poly(hydroxyalkyl acrylate), poly(hydroxyalkyl
methacrylate),
copolymer of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl
acetate,
3
CA 02802180 2016-08-31
WO 2011/1%578
PCT/US2011/039769
carrageenan, galactomannan, or xanthan gum, or a combination thereof. In some
cases, sugar
alcohols can be used in addition to, or in lieu of, hydrophilic polymers.
In another embodiment of this aspect of the invention, the surfactant is
selected from
polyoxyethylene castor oil derivates, mono fatty acid ester of polyoxyethylene
sorbitan,
polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene
glycol fatty acid
ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, or
sorbitan fatty acid mono
ester.
Non-limiting examples of suitable surfactants include polyoxyethyleneglycerol
triricinoleate or polyoxyl 35 castor oil (Cremophor EL; BASF Corp.) or
polyoxyethyleneglycerol
oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor RH
40, also
known as polyoxyl 40 hydrogenated castor oil or macrogolglycerol
hydroxystearate) or
polyethylenglyeol 60 hydrogenated castor oil (Cremophor RH 60), mono fatty
acid ester of
polyoxyethylene sorbitan, such as mono fatty acid ester of polyoxyethylene
(20) sorbitan, e.g.
polyoxyethylene (20) sorbitan monooleate (TweenTm 80), polyoxyethylene (20)
sorbitan
monostearate (Tween 60), polyoxyethylene (20) sorbitan monopalmitate (Tween
40) or
polyoxyethylene (20) sorbitan monolaurate (Tween 20), polyoxyethylene (3)
lauryl ether,
polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether,
polyoxyethylene (5) stearyl
ether, polyoxyethylene (2) nonylphenyl ether, polyoxyethylene (3) nonylphenyl
ether,
polyoxyethylene (4) nonylphenyl ether, polyoxyethylene (3) octylphenyl ether,
PEG-200
monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG-300
distearate,
PEG-300 dioleate, propylene glycol monolaurate (e.g., lauroglycol FCC), D-
alpha-tocopheryl
polyethylene glycol 1000 succinate, sucrose monostearate, sucrose distearate,
sucrose
monolaurate, sucrose dilaurate, sorbitan mono laurate, sorbitan monooleate,
sorbitan
monopalnitate, or sorbitan stearate, or a combination thereof. Other suitable
ionic or non-ionic
surfactants may also be used.
In yet another embodiment of this aspect of the invention, the solid
dispersion is an
amorphous solid dispersion. In still another embodiment, the solid dispersion
is an amorphous
solid dispersion which comprises (1) a compound selected from Compound IA, IB,
lc or ID, or a
pharmaceutically acceptable salt thereof, (2) the hydrophilic polymer, and (3)
the surfactant. In a
further embodiment, the solid dispersion is a solid solution comprising (I) a
compound selected
from Compound IA, IB, Ic or ID, or a pharmaceutically acceptable salt thereof,
and (2) the
hydrophilic polymer. In yet another embodiment, the solid dispersion is a
solid solution
4
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
comprising (1) a compound selected from Compound IA, IB5 Ic or ID, or a
pharmaceutically
acceptable salt thereof, (2) the hydrophilic polymer, and (3) the surfactant.
In yet another embodiment of this aspect of the invention, the hydrophilic
polymer is a
homopolymer or copolymer of N-vinyl pyrrolidone. Preferably, the hydrophilic
polymer is
copovidone.
In still another embodiment, the surfactant is D-alpha-tocopheryl polyethylene
glycol
1000 succinate (vitamin E TPGS). In a further embodiment, the surfactant is
lauroglycol FCC.
In yet another embodiment, the surfactant is a combination of vitamin E TPGS
and lauroglycol
FCC. In still another embodiment, the surfactant is a sorbitan fatty acid
ester, such as sorbitan
mono laurate (Span 20). In another embodiment, the surfactant is selected from
Tween 20,
Tween 80, vitamin E TPGS, or lauroglycol FCC, or a combination thereof
In yet another embodiment, a solid composition of the invention comprises an
amorphous solid dispersion or a solid solution which comprises (1) a compound
selected from
Compound IA, IB, Ic or ID, or a pharmaceutically acceptable salt thereof, (2)
copovidone, and (3)
a surfactant selected from vitamin E TPGS, Span 20, or a combination thereof
In another embodiment, a solid composition of the invention comprises an
amorphous
solid dispersion or a solid solution which comprises (1) a compound selected
from Compound
IA, IB, lc or ID, or a pharmaceutically acceptable salt thereof, (2)
copovidone, and (3) a
combination of vitamin E TPGS and lauroglycol FCC.
In still another embodiment, a solid composition of the invention comprises an
amorphous solid dispersion or a solid solution which comprises (1) a compound
selected from
Compound IA, IB, lc or ID, or a pharmaceutically acceptable salt thereof, (2)
copovidone, and (3)
a surfactant selected from Tween 20 or Tween 80.
In another aspect, the present invention features processes of making a solid
composition of the present invention. In one embodiment, the process comprises
drying a
solvent in a liquid solution, wherein said solution comprises: (1) a compound
selected from
Compound IA, IB, Ic or ID, or a pharmaceutically acceptable salt thereof; (2)
a pharmaceutically
acceptable hydrophilic polymer; and optionally (3) a pharmaceutically
acceptable surfactant.
The drying process can be carried out using any suitable solvent evaporation
techniques
including but not limited to spray-drying techniques.
5
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
In another embodiment, the process comprises solidifying a melt which
comprises: (1)
a compound selected from Compound IA, IB, lc or ID, or a pharmaceutically
acceptable salt
thereof; (2) a pharmaceutically acceptable hydrophilic polymer; and optionally
(3) a
pharmaceutically acceptable surfactant.
A solid composition of the invention may also contain other additives or
ingredients,
such as coloring agents, flavoring agents, lubricants or preservatives. A
solid composition of the
invention can be prepared into any suitable dosage forms, such as capsule,
dragee, granule,
powder, or tablet.
A solid composition of the invention may further comprise another anti-HCV
agent,
for example, an agent selected from HCV helicase inhibitors, HCV polymerase
inhibitors, HCV
protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, cyclophilin
inhibitors, or internal
ribosome entry site (IRES) inhibitors.
The present invention further features methods of using a solid composition of
the
present invention to treat HCV infection. The methods comprise administering a
solid
composition of the present invention to a patient in need thereof, thereby
reducing the blood or
tissue level of HCV virus in the patient.
Other features, objects, and advantages of the present invention are apparent
in the
detailed description that follows. It should be understood, however, that the
detailed description,
while indicating preferred embodiments of the invention, are given by way of
illustration only,
not limitation. Various changes and modifications within the scope of the
invention will become
apparent to those skilled in the art from the detailed description.
DETAILED DESCRIPTION
The present invention features solid compositions comprising (1) a compound
selected
from Compound IA, IB, IC or ID, or a pharmaceutically acceptable salt thereof,
in an amorphous
form, (2) a pharmaceutically acceptable hydrophilic polymer, and optionally
(3) a
pharmaceutically acceptable surfactant. Formulating Compound IA, IB, lc and ID
in an
amorphous form can increase the inherent drug solubility and dissolution rate,
thereby enhancing
the bioavailability of the compound.
A non-limiting way to form an amorphous form of Compound IA, IB, lc or ID (or
a
pharmaceutically acceptable salt thereof) is through the formation of solid
dispersions with a
6
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
polymeric carrier. The presence of hydrophilic polymer(s) and optional
surfactant(s), as well as
the dispersion of Compound IA, IB, lc or ID (or a pharmaceutically acceptable
salt thereof) in an
amorphous form in a matrix containing the polymer(s), can significantly
enhance the dissolution
rate of the compound. In some cases, a solid dispersion formulation can also
effectively
maintain Compound IA, IB, lc or ID (or a pharmaceutically acceptable salt
thereof) in its
supersaturation state to allow for better absorption.
As used herein, the term "solid dispersion" defines a system in a solid state
(as
opposed to a liquid or gaseous state) comprising at least two components,
wherein one
component is dispersed throughout the other component or components. For
example, an active
ingredient or a combination of active ingredients can be dispersed in a matrix
comprised of a
pharmaceutically acceptable hydrophilic polymer(s) and a pharmaceutically
acceptable
surfactant(s). The term "solid dispersion" encompasses systems having small
particles of one
phase dispersed in another phase. These particles are often of less than 400
[tm in size, such as
less than 100, 10, or 1 [tm in size. When a solid dispersion of the components
is such that the
system is chemically and physically uniform or homogenous throughout or
consists of one phase
(as defined in thermodynamics), such a solid dispersion is called a "solid
solution." A glassy
solution is a solid solution in which a solute is dissolved in a glassy
solvent.
The term AUG or AUC0f refers to the area under the plasma concentration time
curve (AUC) extrapolated to infinity.
The terms "weight percent" or "percent by weight" or "% by weight" or "wt %"
denote the weight of an individual component in a composition or mixture as a
percentage of the
weight of the composition or mixture.
In one aspect, the present invention features a solid composition comprising
(1) a
compound selected from Compound IA, IB, lc or ID, or a pharmaceutically
acceptable salt thereof,
in an amorphous form, (2) a pharmaceutically acceptable hydrophilic polymer,
and (3) a
pharmaceutically acceptable surfactant. The compound (or the salt thereof) and
the polymer are
formulated in a solid dispersion. The surfactant may be formulated in the same
solid dispersion;
or the surfactant can be separately combined or mixed with the solid
dispersion.
In one embodiment, a solid composition of the invention comprises an amorphous
solid dispersion which comprises (1) a compound selected from Compound IA, IB,
lc or ID, or a
pharmaceutically acceptable salt thereof, (2) a pharmaceutically acceptable
hydrophilic polymer,
7
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
and (3) a pharmaceutically acceptable surfactant. In another embodiment, a
solid composition of
the invention comprises a solid solution which comprises (1) a compound
selected from
Compound IA, IB, lc or ID, or a pharmaceutically acceptable salt thereof, and
(2) a
pharmaceutically acceptable hydrophilic polymer. In still another embodiment,
a solid
composition of the invention comprises a solid solution which comprises (1) a
compound
selected from Compound IA, IB, lc or ID, or a pharmaceutically acceptable salt
thereof, (2) a
pharmaceutically acceptable hydrophilic polymer, and (3) a pharmaceutically
acceptable
surfactant. In yet another embodiment, a solid composition of the invention
comprises a glassy
solution which includes (1) a compound selected from Compound IA, IB, lc or
ID, or a
pharmaceutically acceptable salt thereof, and (2) a pharmaceutically
acceptable hydrophilic
polymer. In a further embodiment, a solid composition of the invention
comprises a glassy
solution which includes (1) a compound selected from Compound IA, IB, lc or
ID, or a
pharmaceutically acceptable salt thereof, (2) a pharmaceutically acceptable
hydrophilic polymer,
and (3) a pharmaceutically acceptable surfactant.
A solid composition (or a solid dispersion) of the invention can contain, for
example,
at least 1% by weight of Compound IA, IB, lc or ID (or a pharmaceutically
acceptable salt
thereof), preferably at least 5%, including, e.g., at least 10%. For instance,
a solid composition
(or a solid dispersion) of the invention can contain from 1 to 50% by weight
of the compound (or
the salt thereof). For another instance, a solid composition (or a solid
dispersion) of the
invention can contain from 5 to 30% by weight of the compound (or the salt
thereof).
Preferably, a solid composition (or a solid dispersion) of the invention
contains from 5 to 15% by
weight of the compound (or the salt thereof).
A solid dispersion of the invention may contain at least 30% by weight of a
pharmaceutically acceptable hydrophilic polymer or a combination of such
hydrophilic
polymers. Preferably, the solid dispersion contains at least 40% by weight of
a pharmaceutically
acceptable hydrophilic polymer or a combination of such hydrophilic polymers.
More
preferably, the solid dispersion contains at least 50% (including, e.g., at
least 60%, 70%, 80% or
90%) by weight of a pharmaceutically acceptable hydrophilic polymer or a
combination of such
polymers. A solid dispersion (or a solid composition) of the invention may
also contain at least
1% by weight of a pharmaceutically acceptable surfactant or a combination of
such surfactants.
Preferably, the solid dispersion (or solid composition) contains at least 2%
by weight of a
8
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
pharmaceutically acceptable surfactant or a combination of such surfactants.
More preferably,
the solid dispersion (or solid composition) contains from 4% to 20% by weight
of the
surfactant(s), such as from 5% to 10% by weight of the surfactant(s).
In one embodiment, a solid dispersion (or a solid composition) of the
invention
.. comprises at least 30% by weight of a pharmaceutically acceptable
hydrophilic polymer or a
combination of such polymers, and at least 1% by weight of a pharmaceutically
acceptable
surfactant or a combination of such surfactants. In another embodiment, a
solid dispersion (or a
solid composition) of the invention comprises at least 50% by weight of a
pharmaceutically
acceptable hydrophilic polymer or a combination of such polymers, and from 2%
to 20% by
weight of a pharmaceutically acceptable surfactant or a combination of such
surfactants. In yet
another embodiment, a solid dispersion (or a solid composition) of the
invention comprises from
50% to 90% by weight of a pharmaceutically acceptable hydrophilic polymer or a
combination
of such polymers, and from 3% to 15% by weight of a pharmaceutically
acceptable surfactant or
a combination of such surfactants. In yet another embodiment, a solid
dispersion (or a solid
composition) of the invention comprises from 70% to 90% by weight of a
pharmaceutically
acceptable hydrophilic polymer or a combination of such polymers, and from 5%
to 10% by
weight of a pharmaceutically acceptable surfactant or a combination of such
surfactants.
Preferably, a hydrophilic polymer employed in the present invention has a Tg
of at
least 50 C, more preferably at least 60 C, and highly preferably at least 80
C including, but not
limited to from, 80 C to 180 C, or from 100 C to 150 C. Methods for
determining Tg values
of organic polymers are described in INTRODUCTION TO PHYSICAL POLYMER SCIENCE
(2nd
Edition by L.H. Sperling, published by John Wiley & Sons, Inc., 1992). The Tg
value can be
calculated as the weighted sum of the Tg values for homopolymers derived from
each of the
individual monomers, i.e., the polymer Tg = E Wi=X, where W, is the weight
percent of monomer
i in the organic polymer, and X, is the Tg value for the homopolymer derived
from monomer i.
Tg values for the homopolymers may be taken from POLYMER HANDBOOK (2nd Edition
by J.
Brandrup and E.H. Immergut, Editors, published by John Wiley & Sons, Inc.,
1975).
Hydrophilic polymers with a Tg as described above may allow for the
preparation of solid
dispersions that are mechanically stable and, within ordinary temperature
ranges, sufficiently
temperature stable so that the solid dispersions may be used as dosage forms
without further
9
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
processing or be compacted to tablets with only a small amount of tabletting
aids. Hydrophilic
polymers having a Tg of below 50 C may also be used.
Preferably, a hydrophilic polymer employed in the present invention is water-
soluble.
A solid composition of the present invention can also comprise poorly water-
soluble or water-
insoluble polymer or polymers, such as cross-linked polymers. A hydrophilic
polymer
comprised in a solid composition of the present invention preferably has an
apparent viscosity,
when dissolved at 20 C in an aqueous solution at 2 % (w/v), of 1 to 5000
mPa.s., and more
preferably of 1 to 700 mPa.s, and most preferably of 5 to 100 mPa.s.
Hydrophilic polymers suitable for use in a solid composition of the invention
include,
but are not limited to, homopolymers or copolymers of N-vinyl lactams, such as
homopolymers
or copolymers of N-vinyl pyrrolidone (e.g., polyvinylpyrrolidone (PVP), or
copolymers of N-
vinyl pyrrolidone and vinyl acetate or vinyl propionate); cellulose esters or
cellulose ethers, such
as alkylcelluloses (e.g., methylcellulose or ethylcellulose),
hydroxyalkylcelluloses (e.g.,
hydroxypropylcellulose), hydroxyalkylalkylcellulo s es (e.g.,
hydroxypropylmethylcellulose), and
cellulose phthalates or succinates (e.g., cellulose acetate phthalate and
hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose
succinate, or
hydroxypropylmethylcellulose acetate succinate); high molecular polyalkylene
oxides, such as
polyethylene oxide, polypropylene oxide, and copolymers of ethylene oxide and
propylene
oxide; polyacrylates or polymethacrylates, such as methacrylic acid/ethyl
acrylate copolymers,
methacrylic acid/methyl methacrylate copolymers, butyl methacrylate/2-
dimethylaminoethyl
methacrylate copolymers, poly(hydroxyalkyl acrylates), and poly(hydroxyalkyl
methacrylates);
polyacrylamides; vinyl acetate polymers, such as copolymers of vinyl acetate
and crotonic acid,
and partially hydrolyzed polyvinyl acetate (also referred to as partially
saponified "polyvinyl
alcohol"); polyvinyl alcohol; oligo- or polysaccharides, such as carrageenans,
galactomannans,
and xanthan gum; polyhydroxyalkylacrylates; polyhydroxyalkyl-methacrylates;
copolymers of
methyl methacrylate and acrylic acid; polyethylene glycols (PEGs); graft
copolymers of
polyethylene glycol/polyvinyl caprolactam/polyvinyl acetate, or any mixture or
combination
thereof In some cases, sugar alcohols can be used in addition to, or in lieu
of, hydrophilic
polymers.
Non-limiting examples of preferred hydrophilic polymers for the invention
include
polyvinylpyrrolidone (PVP) K17, PVP K25, PVP K30, PVP K90, hydroxypropyl
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
methylcellulose (HPMC) E3, HPMC E5, HPMC E6, HPMC E15, HPMC K3, HPMC A4, HPMC
A15, HPMC acetate succinate (AS) LF, HPMC AS MF, HPMC AS HF, HPMC AS LG, HPMC
AS MG, HPMC AS HG, HPMC phthalate (P) 50, HPMC P 55, Ethocel 4, Ethocel 7,
Ethocel 10,
Ethocel 14, Ethocel 20, copovidone (vinylpyrrolidone-vinyl acetate copolymer
60/40), polyvinyl
acetate, methacrylate/methacrylic acid copolymer (Eudragit) L100-55, Eudragit
L100, Eudragit
S100, polyethylene glycol (PEG) 400, PEG 600, PEG 1450, PEG 3350, PEG 4000,
PEG 6000,
PEG 8000, Soluplus, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer
338, and
poloxamer 407.
Of these, homopolymers or copolymers of N-vinyl pyrrolidone, such as
copolymers of
N-vinyl pyrrolidone and vinyl acetate, are preferred. A non-limiting example
of a preferred
polymer is a copolymer of 60 % by weight of N-vinyl pyrrolidone and 40 % by
weight of vinyl
acetate. Other preferred polymers include, without limitation, hydroxypropyl
methylcellulose
(HPMC, also known as hypromellose in USP), such as hydroxypropyl
methylcellulose grade E5
(HPMC-E5); and hydroxypropyl methylcellulose acetate succinate (HPMC-AS).
A pharmaceutically acceptable surfactant employed in the present invention is
preferably a non-ionic surfactant. Ionic surfactants may also be used. More
preferably, a solid
composition of the present invention comprises a pharmaceutically acceptable
surfactant having
an HLB value of from 2-20. A solid composition of the present invention can
also include a
mixture of pharmaceutically acceptable surfactants, with at least one
surfactant having an HLB
value of no less than 10 and at least another surfactant having an HLB value
of below 10. In one
example, each surfactant comprised in a solid composition of the invention has
an HLB value of
at least 10. In another example, each surfactant comprised in a solid
composition of the
invention has an HLB value of below 10. In yet another example, a solid
composition of the
present invention includes at least two pharmaceutically acceptable
surfactants, one having an
HLB value of at least 10 and the other having an HLB value of below 10. The
HLB system
(Fiedler, H.B., ENCYLOPEDIA OF EXCIPIENTS, 5th ed., Aulendorf: ECV-Editio-
Cantor-Verlag
(2002)) attributes numeric values to surfactants, with lipophilic substances
receiving lower HLB
values and hydrophilic substances receiving higher HLB values.
Non-limiting examples of pharmaceutically acceptable surfactants that are
suitable for
the present invention include polyoxyethylene castor oil derivates, e.g.
polyoxyethyleneglycerol
triricinoleate or polyoxyl 35 castor oil (Cremophor EL; BASF Corp.) or
polyoxyethyleneglycerol
11
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
oxystearate such as polyethylenglycol 40 hydrogenated castor oil (Cremophor RH
40, also
known as polyoxyl 40 hydrogenated castor oil or macrogolglycerol
hydroxystearate) or
polyethylenglycol 60 hydrogenated castor oil (Cremophor RH 60); or a mono
fatty acid ester of
polyoxyethylene sorbitan, such as a mono fatty acid ester of polyoxyethylene
(20) sorbitan, e.g.
polyoxyethylene (20) sorbitan monooleate (Tween 80), polyoxyethylene (20)
sorbitan
monostearate (Tween 60), polyoxyethylene (20) sorbitan monopalmitate (Tween
40), or
polyoxyethylene (20) sorbitan monolaurate (Tween 20). Other non-limiting
examples of suitable
surfactants include polyoxyethylene alkyl ethers, e.g. polyoxyethylene (3)
lauryl ether,
polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether,
polyoxyethylene (5) stearyl
ether; polyoxyethylene alkylaryl ethers, e.g. polyoxyethylene (2) nonylphenyl
ether,
polyoxyethylene (3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether,
polyoxyethylene
(3) octylphenyl ether; polyethylene glycol fatty acid esters, e.g. PEG-200
monolaurate, PEG-200
dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG-300 distearate, PEG-300
dioleate;
alkylene glycol fatty acid mono esters, e.g. propylene glycol monolaurate
(lauroglycol, such as
lauroglycol FCC); sucrose fatty acid esters, e.g. sucrose monostearate,
sucrose distearate, sucrose
monolaurate, sucrose dilaurate; sorbitan fatty acid mono esters such as
sorbitan mono laurate
(Span 20), sorbitan monooleate, sorbitan monopalnitate (Span 40), or sorbitan
stearate; D-alpha-
tocopheryl polyethylene glycol 1000 succinate; or a combination or mixture
thereof Other
suitable surfactants include, but are not limited to, block copolymers of
ethylene oxide and
propylene oxide, also known as polyoxyethylene polyoxypropylene block
copolymers or
polyoxyethylene polypropyleneglycol, such as Poloxamer 124, Poloxamer 188,
Poloxamer 237,
Poloxamer 388, or Poloxamer 407 (BASF Wyandotte Corp.). As described above, a
mixture of
surfactants can be used in a solid composition of the present invention.
Non-limiting examples of preferred surfactants for the invention include to
polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, Cremophor RH
40, Cremophor
EL, Gelucire 44/14, Gelucire 50/13, D-alpha-tocopheryl polyethylene glycol
1000 succinate
(vitamin E TPGS), propylene glycol laurate, sodium lauryl sulfate, and
sorbitan monolaurate.
In one embodiment, a solid composition of the present invention comprises an
amorphous solid dispersion or solid solution which includes (1) a compound
selected from
Compound IA, IB, lc or ID, or a pharmaceutically acceptable salt thereof, and
(2) a
pharmaceutically acceptable hydrophilic polymer. The solid composition also
includes a
12
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
pharmaceutically acceptable surfactant which preferably is formulated in the
amorphous solid
dispersion or solid solution. The hydrophilic polymer can be selected, for
example, from the
group consisting of homopolymer of N-vinyl lactam, copolymer of N-vinyl
lactam, cellulose
ester, cellulose ether, polyalkylene oxide, polyacrylate, polymethacrylate,
polyacrylamide,
polyvinyl alcohol, vinyl acetate polymer, oligosaccharide, and polysaccharide.
As a non-limiting
example, the hydrophilic polymer is selected from the group consisting of
homopolymer of N-
vinyl pyrrolidone, copolymer of N-vinyl pyrrolidone, copolymer of N-vinyl
pyrrolidone and
vinyl acetate, copolymer of N-vinyl pyrrolidone and vinyl propionate,
polyvinylpyrrolidone,
methylcellulose, ethylcellulose, hydroxyalkylcelluloses,
hydroxypropylcellulose,
hydroxyalkylalkylcellulose, hydroxypropylmethylcellulose, cellulose phthalate,
cellulose
succinatc, cellulose acetate phthalate, hydroxypropylmethylcellulose
phthalate,
hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose acetate
succinate,
polyethylene oxide, polypropylene oxide, copolymer of ethylene oxide and
propylene oxide,
graft copolymer of polyethylene glycol/polyvinyl caprolactam/polyvinyl
acetate, methacrylic
acid/ethyl acrylate copolymer, methacrylic acid/methyl methacrylate copolymer,
butyl
methacrylate/2-dimethylaminoethyl methacrylate copolymer, poly(hydroxyalkyl
acrylate),
poly(hydroxyalkyl methacrylate), copolymer of vinyl acetate and crotonic acid,
partially
hydrolyzed polyvinyl acetate, carrageenan, galactomannan, and xanthan gum.
Preferably, the
hydrophilic polymer is selected from polyvinylpyrrolidone (PVP) K17, PVP K25,
PVP K30,
PVP K90, hydroxypropyl methylcellulose (HPMC) E3, HPMC E5, HPMC E6, HPMC E15,
HPMC K3, HPMC A4, HPMC A15, HPMC acetate succinate (AS) LF, HPMC AS MF, HPMC
AS HF, HPMC AS LG, HPMC AS MG, HPMC AS HG, HPMC phthalate (P) 50, HPMC P 55,
EthocelTM 4, EthocelTM 7, EthocelTM 10, EthocelTM 14, EthocelTM 20, copovidone
(vinylpyrrolidone-vinyl
acetate copolymer 60/40), polyvinyl acetate, methacrylate/methacrylic acid
copolymer (EudragitTM)
L100-55, EudragitTM Lioo, EudragitTM S100, polyethylene glycol (PEG) 400, PEG
600, PEG 1450,
PEG 3350, PEG 4000, PEG 6000, PEG 8000, Soluplus, poloxamer 124, poloxamer
188,
poloxamer 237, poloxamer 338, or poloxamer 407. More preferably, the
hydrophilic polymer is
selected from homopolymers of vinylpyrrolidone (e.g., PVP with Fikentscher K
values of from
12 to 100, or PVP with Fikentscher K values of from 17 to 30), or copolymers
of 30 to 70% by
weight of N-vinylpyrrolidone (VP) and 70 to 30% by weight of vinyl acetate
(VA) (e.g., a
copolymer of 60% by weight VP and 40% by weight VA). The surfactant can be
selected, for
13
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
example, from the group consisting of polyoxyethyleneglycerol triricinoleate
or polyoxyl 35
castor oil (Cremophor EL; BASF Corp.) or polyoxyethyleneglycerol oxystearate,
mono fatty
acid ester of polyoxyethylene sorbitan, polyoxyethylene alkyl ether,
polyoxyethylene alkylaryl
ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono
ester, sucrose fatty
acid ester, and sorbitan fatty acid mono ester. As a non-limited example, the
surfactant is
selected from the group consisting of polyethylenglycol 40 hydrogenated castor
oil (Cremophor
RH 40, also known as polyoxyl 40 hydrogenated castor oil or macrogolglycerol
hydroxystearate), polyethylenglycol 60 hydrogenated castor oil (Cremophor RH
60), a mono
fatty acid ester of polyoxyethylene (20) sorbitan (e.g. polyoxyethylene (20)
sorbitan monooleate
(Tween 80), polyoxyethylene (20) sorbitan monostearate (Tween 60),
polyoxyethylene (20)
sorbitan monopalmitatc (Twcen 40), or polyoxyethylcnc (20) sorbitan
monolaurate (Tween 20)),
polyoxyethylene (3) lauryl ether, polyoxyethylene (5) cetyl ether,
polyoxyethylene (2) stearyl
ether, polyoxyethylene (5) stearyl ether, polyoxyethylene (2) nonylphenyl
ether, polyoxyethylene
(3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether, polyoxyethylene
(3) octylphenyl
ether, PEG-200 monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400
dilaurate, PEG-
300 distearate, PEG-300 dioleate, propylene glycol monolaurate, D-alpha-
tocopheryl
polyethylene glycol 1000 succinate, sucrose monostearate, sucrose distearate,
sucrose
monolaurate, sucrose dilaurate, sorbitan monolaurate, sorbitan monooleate,
sorbitan
monopalnitate, and sorbitan stearate. Preferably, the surfactant is selected
from polysorbate 20,
polysorbate 40, polysorbate 60, polysorbate 80, Cremophor RH 40, Cremophor EL,
GelucireTM
44/14, GelucireTM 50/13, D-alpha-tocopheryl polyethylene glycol 1000 succinate
(vitamin E
TPGS), propylene glycol laurate, sodium lauryl sulfate, or sorbitan
monolaurate. More
preferably, the surfactant is selected from sorbitan monolaurate, D-alpha-
tocopheryl
polyethylene glycol 1000 succinate, propylene glycol monolaurate, or a
combination thereof
(e.g., a combination of D-alpha-tocopheryl polyethylene glycol 1000 succinate
and lauroglycol
FCC).
In another embodiment, a solid composition of the present invention comprises
an
amorphous solid dispersion or solid solution which includes (1) a compound
selected from
Compound IA, 1B, Ic or ID, or a pharmaceutically acceptable salt thereof, and
(2) a homopolymer
or copolymer of N-vinyl pyrrolidone (e.g., copovidone). The solid composition
also comprises a
pharmaceutically acceptable surfactant (e.g., vitamin E TPGS, sorbitan
monolaurate, or a
14
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
combination of vitamin E TPGS and lauroglycol FCC), wherein the surfactant
preferably is
formulated in the amorphous solid dispersion or solid solution.
In yet another embodiment, a solid composition of the present invention
comprises an
amorphous solid dispersion or solid solution which includes (1) a compound
selected from
Compound IA, 1B, Ic or ID, or a pharmaceutically acceptable salt thereof, (2)
copovidone, and (3)
a pharmaceutically acceptable surfactant (e.g., vitamin E TPGS, sorbitan
monolaurate, or a
combination of vitamin E TPGS and lauroglycol FCC). The amorphous solid
dispersion or solid
solution may also include another pharmaceutically acceptable surfactant.
In still another embodiment, a solid composition of the present invention
comprises an
amorphous solid dispersion or solid solution which includes (1) 10% by weight
Compound IA,
Ic or ID (or a pharmaceutically acceptable salt thereof) (2) 82% by weight
copovidone, and (3)
5% by weight vitamin E TPGS and 2% by weight lauroglycol FCC. The solid
composition can
also include 1% by weight colloidal silica.
In a further embodiment, a solid composition of the present invention
comprises an
amorphous solid dispersion or solid solution which includes (1) 10% by weight
Compound IA,
IB, IC or ID (or a pharmaceutically acceptable salt thereof) (2) 82% by weight
copovidone, and (3)
7% by weight propylene glycol monocaprylate (Capryol 90). The solid
composition can also
include 1% by weight colloidal silica.
A solid dispersion employed in the present invention preferably comprises or
consists
of a single-phase (defined in thermodynamics) in which the therapeutic
agent(s) (e.g., Compound
IA, IB, IC Or ID, or a pharmaceutically acceptable salt thereof, with or
without another anti-HCV
agent) is molecularly dispersed in a matrix containing the pharmaceutically
acceptable
hydrophilic polymer(s). In such cases, thermal analysis of the solid
dispersion using differential
scanning calorimetry (DSC) typically shows only one single Tg, and the solid
dispersion does not
contain any detectable crystalline Compound IA, IB, Ic or ID as measured by X-
ray powder
diffraction spectroscopy.
Compound IA, I, IC and ID can be prepared according to the procedures
described in
Examples 37, 144, 250 and 237, respectively, of U.S. Patent Application Serial
No. 12/813,301,
filed June 10, 2010, now U.S. Patent Application Publication No. 2010/0317568.
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
A solid composition of the present invention can further include one or more
other
anti-HCV agents. These other anti-HCV agents can be, for example, HCV
polymerase inhibitors
(including nucleoside or non-nucleoside type of polymerase inhibitors), HCV
protease inhibitors,
HCV helicase inhibitors, CD81 inhibitors, cyclophilin inhibitors, internal
ribosome entry site
inhibitors, or HCV NS5A inhibitors. Specific examples of these other anti-HCV
agents include,
but arc not limited to, ribavirin, a-interferon, 3-interferon, pegylated
interferon-a, pegylated
interferon-lambda, PSI-7851 (Pharmasset) (nucleoside polymerase inhibitor),
PSI-938
(Pharmasset) (nucleoside polymerase inhibitor), PF-00868554, ANA-598, IDX184
(nucleoside
polymerase inhibitor), IDX102, IDX375 (non-nucleoside polymerase inhibitor),
GS-9190 (non-
nucleoside polymerase inhibitor), VCH-759, VCH-916, MK-3281, BCX-4678, MK-
3281,
VBY708, ANA598, GL59728, GL60667, BMS-790052 (NS5A inhibitor), BMS-791325
(protease Inhibitor), BMS-650032, BMS-824393, GS-9132, ACH-1095 (protease
inhibitor), AP-
H005, A-831 (Arrow Therapeutics) (NS5A inhibitor), A-689 (Arrow Therapeutics)
(NS5A
inhibitor), 1NX08189 (InhibitexTM) (polymerase inhibitor), AZD2836, telaprevir
(protease
Inhibitor), boceprevir (protease Inhibitor), ITMN-191 (Intermune/Roche), BI-
201335 (protease
Inhibitor), VBY-376, VX-500 (Vertex) (protease Inhibitor), PHX-B, ACH-1625,
IDX136,
1DX316, VX-813 (Vertex) (protease Inhibitor), SCH 900518 (Schering-Plough),
TMC-435
(Tibotec) (protease Inhibitor), ITMN-191 (Intermune, Roche) (protease
Inhibitor), MK-7009
(Merck) (protease Inhibitor), IDX-PI (Novartis), BI-201335 (Boehringer
Ingelheim), R7128
(Roche) (nucleoside polymerase inhibitor), MK-3281 (Merck), MK-0608 (Merck)
(nucleoside
polymerase inhibitor), PF-868554 (Pfizer) (non-nucleoside polymerase
inhibitor), PF-4878691
(Pfizer), IDX-184 (Novartis), IDX-375 (Pharmasset), PPI-461 (Presidio) (NS5A
inhibitor),
B1LB-1941 (Boehringer lngelheim), GS-9190 (Gilead), BMS-790052 (BMS),
AlbuferonTM
(Novartis), ABT-333 (Abbott) (non-nucleoside polymerase inhibitor), and ABT-
072 (Abbott)
(non-nucleoside polymerase inhibitor).
In one embodiment, a solid composition of the invention comprises Compound IA,
in,
Ic or ID (or a pharmaceutically acceptable salt thereof), and a HCV protease
inhibitor. In another
embodiment, a solid composition of the invention comprises Compound IA, IB, lc
or ID (a
pharmaceutically acceptable salt thereof), and a HCV polymerase inhibitor
(e.g., a non-
nucleoside polymerase inhibitor, or preferably a nucleoside polymerase
inhibitor). In yet another
embodiment, a solid composition of the invention comprises (1) Compound IA,
IB, IC or ID (a
16
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
pharmaceutically acceptable salt thereof), (2) a HCV protease inhibitor, and
(3) a HCV
polymerase inhibitor (e.g., a non-nucleoside polymerase inhibitor, or
preferably a nucleoside
polymerase inhibitor). Non-limiting examples of protease and polymerase
inhibitors are
described above. For instance, the protease inhibitor can be selected from ACH-
1095
(Achillion), ACH-1625 (Achillion), ACH-2684 (Achillion), AVL-181 (Avila), AVL-
192
(Avila), BI-201335 (Boehringer Ingelheim), BMS-650032 (BMS), boceprevir,
danoprevir, GS-
9132 (Gilead), GS-9256 (Gilead), GS-9451 (Gilead), IDX-136 (Idenix), IDX-316
(Idenix), IDX-
320 (Idenix), MK-5172 (Merck), narlaprevir, PHX-1766 (Phenomix), telaprevir,
TMC-435
(Tibotec), vaniprevir, VBY708 (Virobay), VX-500 (Vertex), VX-813 (Vertex), VX-
985
(Vertex), or a combination thereof And the HCV polymerase inhibitor can be
selected from,
without limitation, ABT-072 (Abbott), ABT-333 (Abbott), ANA-598 (Anadys), BI-
207127
(Boehringer Ingelheim), BILB-1941 (Boehringer Ingelheim), BMS-791325 (BMS),
filibuvir,
GL59728 (Glaxo), GL60667 (Glaxo), GS-9669 (Gilead), IDX-375 (Idenix), MK-3281
(Merck),
tegobuvir, TMC-647055 (Tibotec), VCH-759 (Vertex & ViraChem), VCH-916
(ViraChem),
VX-222 (VCH-222) (Vertex & ViraChem), VX-759 (Vertex), GS-6620 (Gilead), IDX-
102
(Idenix), IDX-184 (Idenix), INX-189 (Inhibitex), MK-0608 (Merck), PSI-7977
(Pharmasset),
PSI-938 (Pharmasset), RG7128 (Roche), TMC64912 (Medivir), GSK625433
(GlaxoSmithKline), BCX-4678 (BioCryst), or a combination thereof The
polymerase inhibitor
may be a nucleotide polymerase inhibitor, such as GS-6620 (Gilead), IDX-102
(Idenix), IDX-
184 (Idenix), INX-189 (Inhibitex), MK-0608 (Merck), PSI-7977 (Pharmasset), PSI-
938
(Pharmasset), RG7128 (Roche), TMC64912 (Medivir), or a combination therefore.
The
polymerase inhibitor may also be a non-nucleoside polymerase inhibitor, such
as ABT-072
(Abbott), ABT-333 (Abbott), ANA-598 (Anadys), BI-207127 (Boehringer
Ingelheim), BILB-
1941 (Boehringer Ingelheim), BMS-791325 (BMS), filibuvir, GL59728 (Glaxo),
GL60667
(Glaxo), GS-9669 (Gilead), IDX-375 (Idenix), MK-3281 (Merck), tegobuvir, TMC-
647055
(Tibotec), VCH-759 (Vertex & ViraChem), VCH-916 (ViraChem), VX-222 (VCH-222)
(Vertex
& ViraChem), VX-759 (Vertex), or a combination thereof. The present invention
also
contemplates the inclusion of both a nucleotide polymerase inhibitor and a non-
nucleoside
polymerase inhibitor in a solid composition of the invention.
In yet another embodiment, a solid composition of the invention comprises (1)
Compound IA, IB, IC or ID (a pharmaceutically acceptable salt thereof), and
(2) INX-189
17
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
yM
õ0
14F1,
1:1
(Inhibitex;
). In still another embodiment, a solid composition of the
invention comprises (1) Compound IA, IB, Ic or ID (a pharmaceutically
acceptable salt thereof),
and (2) RG7128, PSI-7977, PSI-938 or PSI-7851. In a further embodiment, a
solid composition
of the invention comprises (1) Compound IA, IB, Ic or ID (a pharmaceutically
acceptable salt
thereof), (2) MK-5172, and optionally (3) RG7128. In another embodiment, a
solid composition
of the invention comprises (1) Compound IA, IB, Ic or ID (a pharmaceutically
acceptable salt
thereof), (2) BMS-650032, and optionally (3) PSI-7977, PSI-938 or PSI-7851. In
another
embodiment, a solid composition of the invention comprises (1) Compound IA,
IB, lc or ID (a
pharmaceutically acceptable salt thereof), (2) danoprevir, and optionally (3)
RG7128, PSI-7977,
PSI-938 or PSI-7851. In another embodiment, a solid composition of the
invention comprises
(1) Compound IA, IB, Ic or ID (a pharmaceutically acceptable salt thereof),
(2) TMC-435, and
optionally (3) RG7128, PSI-7977, PSI-938 or PSI-7851. In another embodiment, a
solid
composition of the invention comprises (1) Compound IA, IB, Ic or ID (a
pharmaceutically
acceptable salt thereof), (2) BMS-650032, and optionally (3) BMS-790052.
Compound IA, IB, IC
or ID (a pharmaceutically acceptable salt thereof), and BMS-790052, can be co-
formulated in an
amorphous form, e.g., co-formulated in a solid dispersion or solid solution
described herein. In
still another embodiment, a solid composition of the invention comprises (1)
Compound IA, IB, Ic
or ID (a pharmaceutically acceptable salt thereof), and (2) GS-9256, GS-9190,
GS-9132, GS-
9451, GS-9669, or GS-6620.
Compound IA, IB, Ic or ID (a pharmaceutically acceptable salt thereof), and
one or
more other anti-HCV agents described herein (e.g., MX-5172 or danoprevir), can
be co-
formulated in amorphous forms, e.g., co-formulated in a solid dispersion or
solid solution
described herein. Alternatively, Compound IA, IB, Ic or ID (a pharmaceutically
acceptable salt
thereof) can be co-administered with one or more other anti-HCV agents
described herein, either
.. concurrently or sequentially, to a patient in need thereof for the
treatment of HCV infection.
A solid composition of the present invention preferably is a solid oral dosage
form.
Common solid oral dosage forms suitable for the present invention include, but
are not limited
to, capsules, dragees, granules, pills, powders and tablets, with capsules and
tablets being
18
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
preferred. A solid oral dosage form of the present invention can also include
other excipients or
inset diluents, such as sucrose, lactose or starch. Lubricants, coloring
agents, releasing agents,
coating agents, sweetening or flavoring agents, buffering agents,
preservatives, or antioxidants
can also be included in a solid oral dosage form of the present invention.
A solid composition of the present invention can be prepared by a variety of
techniques such as, without limitation, melt-extrusion, spray-drying, co-
precipitation, freeze
drying, or other solvent evaporation techniques, with melt-extrusion and spray-
drying being
preferred. The melt-extrusion process typically comprises the steps of
preparing a melt which
includes the active ingredient(s), the hydrophilic polymer(s) and preferably
the surfactant(s), and
then cooling the melt until it solidifies. Melting often involves a transition
into a liquid state in
which it is possible for one component to get dissolved or embedded,
preferably homogeneously
dissolved or embedded, in the other component or components. In many cases,
the polymer
component(s) will melt and the other components including the active
ingredient(s) and
surfactant(s) will dissolve in the melt thereby forming a solution. In such a
case, the polymer
functions as a solvent. Melting usually involves heating above the softening
point of the
polymer(s). The preparation of the melt can take place in a variety of ways.
The mixing of the
components can take place before, during or after the formation of the melt.
For example, the
components can be mixed first and then melted or be simultaneously mixed and
melted. The
melt can also be homogenized in order to disperse the active ingredient(s)
efficiently. In
addition, it may be convenient first to melt the polymer(s) and then to mix in
and homogenize the
active ingredient(s). In one example, all materials except surfactant(s) are
blended and fed into
an extruder, while the surfactant(s) is molten externally and pumped in during
extrusion.
In another example, the melt comprises Compound IA, IB, Ic or ID (a
pharmaceutically
acceptable salt thereof), and one or more hydrophilic polymers described
above; and the melt
temperature is in the range of from 100 to 170 C, preferably from 120 to 150
C, and highly
preferably from 135 to 140 C. The melt can also include a pharmaceutically
acceptable
surfactant described above.
In still another example, the melt comprises Compound IA, IB, Ic or ID (a
pharmaceutically acceptable salt thereof), at least another anti-HCV agent
described above, and
one or more hydrophilic polymers described above.
The melt can also include a
pharmaceutically acceptable surfactant described above.
19
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
To start a melt-extrusion process, the active ingredient(s) (e.g., Compound
IA, IB, lc or
ID (a pharmaceutically acceptable salt thereof), or a combination of Compound
IA, IB, lc or ID (a
pharmaceutically acceptable salt thereof) with at least another anti-HCV
agent) can be employed
in their solid forms, such as their respective crystalline forms. The active
ingredient(s) can also
be employed as a solution or dispersion in a suitable liquid solvent such as
alcohols, aliphatic
hydrocarbons, esters or, in some cases, liquid carbon dioxide. The solvent can
be removed, e.g.
evaporated, upon preparation of the melt.
Various additives can also be included in the melt, for example, flow
regulators (e.g.,
colloidal silica), binders, lubricants, fillers, disintegrants, plasticizers,
colorants, or stabilizers
(e.g., antioxidants, light stabilizers, radical scavengers, and stabilizers
against microbial attack).
The melting and/or mixing can take place in an apparatus customary for this
purpose.
Particularly suitable ones are extruders or kneaders. Suitable extruders
include single screw
extruders, intermeshing screw extruders or multiscrew extruders, preferably
twin screw
extruders, which can be corotating or counterrotating and, optionally, be
equipped with kneading
disks. It will be appreciated that the working temperatures will be determined
by the kind of
extruder or the kind of configuration within the extruder that is used. Part
of the energy needed
to melt, mix and dissolve the components in the extruder can be provided by
heating elements.
However, the friction and shearing of the material in the extruder may also
provide a substantial
amount of energy to the mixture and aid in the formation of a homogeneous melt
of the
components.
The melt can range from thin to pasty to viscous. Shaping of the extrudate can
be
conveniently carried out by a calender with two counter-rotating rollers with
mutually matching
depressions on their surface. The extrudate can be cooled and allow to
solidify. The extrudate
can also be cut into pieces, either before (hot-cut) or after solidification
(cold-cut).
The solidified extrusion product can be further milled, ground or otherwise
reduced to
granules. The solidified extrudate, as well as each granule produced,
comprises a solid
dispersion, preferably a solid solution, of the active ingredient(s) in a
matrix comprised of the
hydrophilic polymer(s) and optionally the pharmaceutically acceptable
surfactant(s). Where the
granules do not contain any surfactant, a pharmaceutically acceptable
surfactant described above
can be added to and blended with the granules. The extrusion product can also
be blended with
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
other active ingredient(s) and/or additive(s) before being milled or ground to
granules. The
granules can be further processed into suitable solid oral dosage forms.
In some cases, direct-shaping techniques such as injection moulding can be
used in
combination with melt extrusion to prepare suitable solid dosage forms.
In one example, copovidone and one or more surfactants are mixed and
granulated,
followed by the addition of aerosil and Compound IA, IB, Ic or ID (a
pharmaceutically acceptable
salt thereof). The mixture, which may contain for example at least 5% by
weight of Compound
IA, IB, lc or ID (a pharmaceutically acceptable salt thereof) is then milled.
The mixture is then
subject to extrusion, and the extrudate thus produced can be milled and sieved
for further
processing to make capsules or tablets. Surfactant(s) employed in this example
can also be
added through liquid dosing during extrusion.
The approach of solvent evaporation, via spray-drying, provides the advantage
of
allowing for processability at lower temperatures, if needed, and allows for
other modifications
to the process in order to further improve powder properties. The spray-dried
powder can then
be formulated further, if needed, and final drug product is flexible with
regards to whether
capsule, tablet or any other solid dosage form is desired.
Exemplary spray-drying processes and spray-drying equipment are described in
K.
Masters, SPRAY DRYING HANDBOOK (Halstead Press, New York, 4th ed., 1985). Non-
limiting
examples of spray-drying devices that are suitable for the present invention
include spray dryers
manufactured by Niro Inc. or GEA Process Engineering Inc., Buchi Labortechnik
AG, and Spray
Drying Systems, Inc. A spray-drying process generally involves breaking up a
liquid mixture
into small droplets and rapidly removing solvent from the droplets in a
container (spray drying
apparatus) where there is a strong driving force for evaporation of solvent
from the droplets.
Atomization techniques include, for example, two-fluid or pressure nozzles, or
rotary atomizers.
The strong driving force for solvent evaporation can be provided, for example,
by maintaining
the partial pressure of solvent in the spray drying apparatus well below the
vapor pressure of the
solvent at the temperatures of the drying droplets. This may be accomplished
by either (1)
maintaining the pressure in the spray drying apparatus at a partial vacuum;
(2) mixing the liquid
droplets with a warm drying gas (e.g., heated nitrogen); or (3) both.
The temperature and flow rate of the drying gas, as well as the spray dryer
design, can
be selected so that the droplets are dry enough by the time they reach the
wall of the apparatus.
21
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
This help to ensure that the dried droplets are essentially solid and can form
a fine powder and do
not stick to the apparatus wall. The spray-dried product can be collected by
removing the
material manually, pneumatically, mechanically or by other suitable means. The
actual length of
time to achieve the preferred level of dryness depends on the size of the
droplets, the
formulation, and spray dryer operation. Following the solidification, the
solid powder may stay
in the spray drying chamber for additional time (e.g., 5-60 seconds) to
further evaporate solvent
from the solid powder. The final solvent content in the solid dispersion as it
exits the dryer is
preferably at a sufficiently low level so as to improve the stability of the
final product. For
instance, the residual solvent content of the spray-dried powder can be less
than 2% by weight.
Highly preferably, the residual solvent content is within the limits set forth
in the International
Conference on Harmonization (ICH) Guidelines. In addition, it may be useful to
subject the
spray-dried composition to further drying to lower the residual solvent to
even lower levels.
Methods to further lower solvent levels include, but are not limited to, fluid
bed drying, infra-red
drying, tumble drying, vacuum drying, and combinations of these and other
processes.
Like the solid extrudate described above, the spray dried product contains a
solid
dispersion, preferably a solid solution, of the active ingredient(s) in a
matrix comprised of the
hydrophilic polymer(s) and optionally the pharmaceutically acceptable
surfactant(s). Where the
spray dried product does not contain any surfactant, a pharmaceutically
acceptable surfactant
described above can be added to and blended with the spray-dried product
before further
processing.
Before feeding into a spray dryer, the active ingredient(s) (e.g., Compound
IA, IB, lc or
ID (a pharmaceutically acceptable salt thereof), or a combination of Compound
IA, IB, lc or ID (a
pharmaceutically acceptable salt thereof) with at least another anti-HCV
agent), the hydrophilic
polymer(s), as well as other optional active ingredients or excipients such as
the
pharmaceutically acceptable surfactant(s), can be dissolved in a solvent.
Suitable solvents
include, but are not limited to, water, alkanols (e.g., methanol, ethanol, 1-
propanol, 2-propanol or
mixtures thereof), acetone, acetone/water, alkanol/water mixtures (e.g.,
ethanol/water mixtures),
or combinations thereof. The solution can also be preheated before being fed
into the spray
dryer.
The solid dispersion produced by melt-extrusion, spray-drying or other
techniques can
be prepared into any suitable solid oral dosage forms. In one embodiment, the
solid dispersion
22
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
prepared by melt-extrusion, spray-drying or other techniques (e.g., the
extrudate or the spray-
dried powder) can be compressed into tablets. The solid dispersion can be
either directly
compressed, or milled or ground to granules or powders before compression.
Compression can
be done in a tablet press, such as in a steel die between two moving punches.
When a solid
composition of the present invention comprises Compound IA, IB, IC or ID (a
pharmaceutically
acceptable salt thereof) and another anti-HCV agent, it is possible to
separately prepare solid
dispersions of each individual active ingredient and then blend the optionally
milled or ground
solid dispersions before compacting. Compound IA, IB, lc or ID (a
pharmaceutically acceptable
salt thereof) and other active ingredient(s) can also be prepared in the same
solid dispersion,
.. optionally milled and/or blended with other additives, and then compressed
into tablets.
At least one additive selected from flow regulators, binders, lubricants,
fillers,
disintegrants, or plasticizers may be used in compressing the solid
dispersion. These additives
can be mixed with ground or milled solid dispersion before compacting.
Disintegrants promote a
rapid disintegration of the compact in the stomach and keeps the liberated
granules separate from
one another. Non-limiting examples of suitable disintegrants are cross-linked
polymers such as
cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethylcellulose
or sodium
croscarmellose. Non-limiting examples of suitable fillers (also referred to as
bulking agents) are
lactose monohydrate, calcium hydrogenphosphate, microcrystalline cellulose
(e.g., Avicell),
silicates, in particular silicium dioxide, magnesium oxide, talc, potato or
corn starch, isomalt, or
.. polyvinyl alcohol. Non-limiting examples of suitable flow regulators
include highly dispersed
silica (e.g., colloidal silica such as Aerosil), and animal or vegetable fats
or waxes. Non-limiting
examples of suitable lubricants include polyethylene glycol (e.g., having a
molecular weight of
from 1000 to 6000), magnesium and calcium stearates, sodium stearyl fumarate,
and the like.
Various other additives may also be used in preparing a solid composition of
the
present invention, for example dyes such as azo dyes, organic or inorganic
pigments such as
aluminium oxide or titanium dioxide, or dyes of natural origin; stabilizers
such as antioxidants,
light stabilizers, radical scavengers, stabilizers against microbial attack.
Solid compositions according to certain embodiments of the present invention
may
contain several layers, for example laminated or multilayer tablets. They can
be in open or
closed form. "Closed dosage forms" are those in which one layer is completely
surrounded by at
least one other layer.
23
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
In order to facilitate the intake of a solid dosage form, it is advantageous
to give the
dosage form an appropriate shape. Large tablets that can be swallowed
comfortably are
therefore preferably elongated rather than round in shape.
A film coat on the tablet further contributes to the ease with which it can be
swallowed. A film coat also improves taste and provides an elegant appearance.
The film-coat
usually includes a polymeric film-forming material such as hydroxypropyl
methylcellulose,
hydroxypropylcellulose, and acrylate or methacrylate copolymers. Besides a
film-forming
polymer, the film-coat may further comprise a plasticizer, e.g. polyethylene
glycol, a surfactant,
e.g. polysorbates, and optionally a pigment, e.g. titanium dioxide or iron
oxides. The film-
.. coating may also comprise talc as anti-adhesive. Preferably, the film coat
accounts for less than
5 % by weight of a pharmaceutical composition of the present invention.
In another aspect, the present invention feature methods of using solid
compositions of
the present invention to treat HIV infection. The methods comprise
administering a solid
composition of the present invention to a patient in need thereof. A solid
composition of the
.. present invention can be administered either alone, or in combination with
one or more other
anti-HCV agents, such as those described hereinabove. The specific inhibitory
dose for any
particular patient will depend upon a variety of factors including the
severity of the HCV
infection; the activity of the active ingredient(s) in the particular patient;
the specific solid
composition employed; the age, body weight, general health, sex and diet of
the patient; the time
of administration and rate of excretion; the duration of the treatment; drugs
used in combination
or coincidental with Compound IA, ILI, Ic or ID; and like factors well known
in the medical arts.
In one embodiment, a method of the present invention comprises administering
to a
patient in need thereof a solid composition of the present invention and at
least another anti-HCV
agent, wherein said another anti-HCV agent is selected from HCV polymerase
inhibitors (e.g.,
nucleoside or non-nucleoside HCV polymerase inhibitors), HCV protease
inhibitors, HCV
helicase inhibitors, CD81 inhibitors, cyclophilin inhibitors, internal
ribosome entry site
inhibitors, or HCV NS5A inhibitors. Preferably, said another anti-HCV agent is
an HCV
polymerase inhibitor (e.g., nucleoside or non-nucleoside HCV polymerase
inhibitor) or an HCV
protease inhibitor. Also preferably, said another anti-HCV agent is interferon
or ribavirin, or
.. preferably a combination thereof. The interferon preferably is a-
interferon, and more preferably,
pegylated interferon-a such as PEGASYSTM (peginterferon alfa-2a). The
administration of a solid
24
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
composition of the present invention and another anti-HCV agent(s) can be
concurrent or
sequential.
The present invention also features use of a solid composition of the present
invention
for the manufacture of medicaments for the treatment of HCV infection.
It should be understood that the above-described embodiments and the following
examples are given by way of illustration, not limitation. Various changes and
modifications
within the scope of the present invention will become apparent to those
skilled in the art from the
present description.
Example 1
Compound IA was extruded using melt-extrusion. Two extrudates were prepared,
and
then milled and filled into capsules. The 1st extrudate contained Compound IA,
copovidone, and
Vitamin E-TPGS in a weight ratio of 5:88:7 (hereinafter Formulation 1). The
2nd extrudate
contained Compound IA, copovidone and Sorbitan monolaurate in a weight ratio
of 5:90:5
(hereinafter Formulation 2). The extrusion mixtures were prepared by use of
mortar and pestle.
Both formulations were extruded at 140 C. The obtained extruded strands were
milled and the
fractions of over 0.2 mm were combined with 100 mg mannite / collidal silica
(99:1) and then
filled into capsules. Each of these extrudate capsules contained 5 mg Compound
IA.
Example 2
The pharmacokinetic profile of each formulation described in Example 1 was
evaluated in dogs after single oral (PO) administration of the formulation.
Four dogs (two male
and two female dogs) were used in this study. The animals were fasted
overnight and received
food 30 min prior to dosing and throughout the duration of the study. Plasma
samples were
collected at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post-dose
administration. Plasma samples
were analyzed for Compound IA by LC-MS/MS. AUC0f and C. were normalized to a
dose of
0.5 mg/kg Compound IA.
Mean dose-normalized AUCo-inf values of Compound IA were 512.2 and 432.0
ng=h/ml, at a 0.5 mg/kg dose in Formulations 1 and 2, respectively. Mean dose-
normalized C.
values of Compound IA were 36.1 and 15.2 ng/ml at a 0.5 mg/kg dose in
Formulations 1 and 2,
respectively.
CA 02802180 2016-08-31
WO 2011/156578
PCT/US2011/039769
Example 3
Compound IA was mixed with hydrophilic polymers and pharmaceutically
acceptable
surfactants at various ratios, and dissolved in an organic solvent (acetone or
acetone/water
mixtures). The solvent was then removed from the system under heat (-75 C) and
vacuum,
using a Genevac rotary evaporator or Buchi Rotavap. Solid dispersions of
Compound IA at
various drug loading levels and using different surfactants or polymers were
sieved through a 30
mesh screen to reduce particle size. The resultant solid dispersion samples
were used for
amorphous characterization by X-ray powder diffraction (PXRD), chemical
stability, in-vitro
dissolution test and dog bioavailability studies.
For dog bioavailability studies, the solid dispersion powder was mixed with
other
excipients and compressed into tablets to achieve strengths of 0.5 mg, 5.0 mg,
and 25.0 mg. For
in-vitro dissolution studies, the release of Compound IA was evaluated.
The hydrophilic polymers employed were copovidone, SoluplusTM, hydroxypropyl
methylcellulose phthalate (HPMCP), and hydroxypropyl methylcellulose grade E5
(HPMC-E5).
The surfactants employed were Vitamin E TPGS and Cremophor RH40. The amount of
the
surfactant(s) in each solid dispersion was no more than 10% by weight, and the
amount of
Compound IA in each solid dispersion ranged from 5 to 20% by weight.
All solid dispersions showed that Compound IA was in an amorphous form, as
indicated by their PXRD patterns. Solid dispersions containing copovidone were
evaluated for
stability and showed chemical stability after 4 weeks at 40 C and 75%
relative humidity in
closed dish studies. These solid dispersions also exhibited rapid dissolution
rate.
Example 4
One solid dispersion formulation was prepared using spray-drying to produce a
solid
dispersion powder of amorphous Compound IA within a polymer matrix. The spray
dried
powder contained 10% by weight of Compound IA, 85% by weight of copovidone,
and 5% by
weight of Vitamin E TPGS. Acetone and water in a 9:1 ratio was used as a
solvent for spray-
drying.
The spray dried powder was further dried under vacuum to remove residual
solvent.
The vacuum dried powder was blended with microcrystalline cellulose, lactose
monohydrate,
26
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
colloidal silicon dioxide, sodium stearyl fumarate, and optionally
croscarmellose sodium. This
blend was then compressed into the final tablet dosage form.
Example 5
Compound IB was formulated using melt-extrusion as well as spray-drying. Both
formulations contained 10% Compound IB, 82% copovidone, 2% Vitamin E TPGS, 5%
lauroglycol FCC, and 1% Aerosil 200, and were processed further into
compressed tablets. Both
forms were tested in an accelerated stability test over 4 weeks. The
pharmacokinetic study in
dogs showed excellent bioavailability of Compound IB.
Example 6
Compound Ic was mixed with Copovidone at drug loading of 10%, and dissolved in
an organic solvent (e.g. methanol). The solvent was then removed from the
system under heat
(-40 C) and vacuum. The resultant amorphous solid dispersions were
characterized by polarized
light microscopy (PLM) and in vitro dissolution test. For in-vitro dissolution
studies, the release
of Compound lc from above amorphous solid dispersions was evaluated in pH 6.8
phosphate
buffer by in situ UV dip probe and HPLC assay.
The solid dispersion showed that Compound Ic was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound Ic in neat amorphous state.
Example 7
Compound Ic was mixed with Copovidone and Vitamin E TPGS at drug loading of
10% and 20%, respectively, and dissolved in an organic solvent (e.g.
methanol). The solvent
was then removed from the system under heat (-40 C) and vacuum (rotary
evaporation or
vacuum oven). Solid dispersion of Compound Ic at 10% drug loading level was
ground to fine
particles using mortar and pestle, and was then characterized by X-ray powder
diffraction
(PXRD), DSC and TGA, and in vitro dissolution test. The resultant amorphous
solid dispersion
at 20% drug loading was also characterized by polarized light microscopy (PLM)
and in vitro
dissolution test. For in-vitro dissolution studies, the release of Compound Ic
from above
27
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by in
situ UV dip probe
and HPLC assay.
Both solid dispersions showed that Compound Ic was in an amorphous form, as
indicated by PXRD, DSC or PLM. These solid dispersions exhibited rapid
dissolution rate in
comparison with Compound Ic in neat amorphous state.
Example 8
Compound Ic was mixed with Copovidone and Tween 80 or Cremophor RH40 at drug
loading of 10% and 20%, respectively, and dissolved in an organic solvent
(e.g. methanol). The
solvent was then removed from the system under heat (-40 C) and vacuum. The
resultant
amorphous solid dispersions were characterized by polarized light microscopy
(PLM) and in
vitro dissolution test. For in-vitro dissolution studies, the release of
Compound Ic from above
amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by in
situ UV dip probe
and HPLC assay.
All four solid dispersions showed that Compound Ic was in an amorphous form,
as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound Ic in neat amorphous state.
Example 9
Compound Ic was mixed with Copovidone and Vitamin E TPGS and Lauroglycol
FCC at drug loading of 10% and 20%, respectively, and dissolved in an organic
solvent (e.g.
methanol). The solvent was then removed from the system under heat (-40 C) and
vacuum. The
resultant amorphous solid dispersions were characterized by polarized light
microscopy (PLM)
and in vitro dissolution test. For in-vitro dissolution studies, the release
of Compound Ic from
above amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by
in situ UV dip
probe and HPLC assay.
Both solid dispersions showed that Compound Ic was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound Ic in neat amorphous state.
Example 10
28
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
Compound Ic was mixed with Soluplus and Vitamin E TPGS or Tween 80 or
Cremophor RH40 at drug loading of 10% and 20%, respectively, and dissolved in
an organic
solvent (e.g. methanol). The solvent was then removed from the system under
heat (-40 C) and
vacuum. The resultant amorphous solid dispersions were characterized by
polarized light
microscopy (PLM) and in vitro dissolution test. For in-vitro dissolution
studies, the release of
Compound lc from above amorphous solid dispersions was evaluated in pH 6.8
phosphate buffer
by in situ UV dip probe and HPLC assay.
All six solid dispersions showed that Compound Ic was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound Ic in neat amorphous state.
Example 11
Compound lc was mixed with Soluplus (a graft copolymer of polyethylene glycol,
polyvinyl caprolactam and polyvinyl acetate) and Vitamin E TPGS and
Lauroglycol FCC at drug
loading of 10% and 20%, respectively, and dissolved in an organic solvent
(e.g. methanol). The
solvent was then removed from the system under heat (-40 C) and vacuum. The
resultant
amorphous solid dispersions were characterized by polarized light microscopy
(PLM) and in
vitro dissolution test. For in-vitro dissolution studies, the release of
Compound Ic from above
amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by in
situ UV dip probe
and HPLC assay.
Both solid dispersions showed that Compound Ic was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound Ic in neat amorphous state.
Example 12
One solid dispersion formulation was prepared using spray-drying to produce a
solid
dispersion powder of amorphous Compound Ic within a polymer matrix. The spray
dried powder
contained 10% by weight of Compound Ic, 85% by weight of Copovidone, and 5% by
weight of
Vitamin E TPGS. Methanol was used as a solvent for spray drying. The spray
dried powder was
further dried under vacuum to further remove residual solvent. The dried
amorphous solid
dispersion was characterized by X-ray powder diffraction (PXRD), DSC and TGA.
29
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
The solid dispersion showed that Compound Ic was in an amorphous form, as
indicated by either PXRD and DSC.
Example 13
Compound ID was mixed with Copovidone at drug loading of 10%, and dissolved
in an organic solvent (e.g. methanol). The solvent was then removed from the
system under heat
(-40 C) and vacuum. The resultant amorphous solid dispersions were
characterized by polarized
light microscopy (PLM) and in vitro dissolution test. For in-vitro dissolution
studies, the release
of Compound ID from above amorphous solid dispersions was evaluated in pH 6.8
phosphate
buffer by in situ UV dip probe and HPLC assay.
The solid dispersion showed that Compound ID was in an amorphous form, as
indicated by PLM.
These solid dispersions also exhibited rapid dissolution rate in comparison
with Compound ID in
neat amorphous state.
Example 14
Compound ID was mixed with Copovidone and Vitamin E TPGS or Tween 80 or
Cremophor RH40 at drug loading of 10% and 20%, respectively, and dissolved in
an organic
solvent (e.g. methanol). The solvent was then removed from the system under
heat (-40 C) and
vacuum. The resultant amorphous solid dispersions were characterized by
polarized light
microscopy (PLM) and in vitro dissolution test. For in-vitro dissolution
studies, the release of
Compound ID from above amorphous solid dispersions was evaluated in pH 6.8
phosphate buffer
by in situ UV dip probe and HPLC assay.
All six solid dispersions showed that Compound ID was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound ID in neat amorphous state.
Example 15
Compound ID was mixed with Copovidone and Vitamin E TPGS and Lauroglycol
FCC at drug loading of 10% and 20%, respectively, and dissolved in an organic
solvent (e.g.
methanol). The solvent was then removed from the system under heat (-40 C) and
vacuum. The
resultant amorphous solid dispersions were characterized by polarized light
microscopy (PLM)
and in vitro dissolution test. For in-vitro dissolution studies, the release
of Compound ID from
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
above amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by
in situ UV dip
probe and HPLC assay.
Both solid dispersions showed that Compound ID was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound ID in neat amorphous state.
Example 16
Compound ID was mixed with Soluplus and Vitamin E TPGS or Tween 80 or
Cremophor RH40 at drug loading of 10% and 20%, respectively, and dissolved in
an organic
solvent (e.g. methanol). The solvent was then removed from the system under
heat (-40 C) and
vacuum. The resultant amorphous solid dispersions were characterized by
polarized light
microscopy (PLM) and in vitro dissolution test. For in-vitro dissolution
studies, the release of
Compound ID from above amorphous solid dispersions was evaluated in pH 6.8
phosphate buffer
by in situ UV dip probe and HPLC assay.
All six solid dispersions showed that Compound ID was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound ID in neat amorphous state.
Example 17
Compound ID was mixed with Soluplus and Vitamin E TPGS and Lauroglycol
FCC at drug loading of 10% and 20%, respectively, and dissolved in an organic
solvent (e.g.
methanol). The solvent was then removed from the system under heat (-40 C) and
vacuum. The
resultant amorphous solid dispersions were characterized by polarized light
microscopy (PLM)
and in vitro dissolution test. For in-vitro dissolution studies, the release
of Compound ID from
above amorphous solid dispersions was evaluated in pH 6.8 phosphate buffer by
in situ UV dip
probe and HPLC assay.
Both solid dispersions showed that Compound ID was in an amorphous form, as
indicated by PLM. These solid dispersions also exhibited rapid dissolution
rate in comparison
with Compound ID in neat amorphous state.
Example 18
31
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
Granulation of one formulation containing 15% Compound IB, 7.1% Lauroglycol
FCC, 2.9% Vitamin E TPGS and 75% copovidone was performed using a lab mill.
Liquid
excipients such as Lauroglycol FCC were granulated with the solid raw
material, stored in the
refrigerator over night for setting and mixed again. The resultant blends were
used directly for
extrusion. Extrusion was carried out on a small-scale twin-screw extruder
(rotation speed of 80
rpm) at a temperature of 140 C. Drug recovery and purity analysis after
processing was
evaluated by HPLC assay. The solid dispersion was characterized by DSC and
polarized light
microscopy (PLM). For in-vitro dissolution studies, the release of Compound IB
from above
amorphous solid dispersion was evaluated in pH 6.8 phosphate buffer by HPLC
assay.
DSC and PLM analysis of the solid dispersion revealed that Compound IB was in
an amorphous form and showed negligible degradation upon processing at high
temperature.
The solid dispersion exhibited rapid dissolution rate at pH 6.8.
It turned out that Compound IB can be processed via melt extrusion at
temperatures as high as about 170 C, which is far beyond the degradation
temperature of the
drug substance of around 130 C without an increase in API degradation.
Example 19
Compound IB was formulated using melt-extrusion as well as spray-drying. Both
formulations included 10% Compound IB, 82% copovidone, 5% Lauroglycol FCC, 2%
Vitamin
E TPGS, and 1% Aerosil 200. Preparation of the granulate for melt extrusion
was performed
using a lab mill. Liquid excipients such as Lauroglycol FCC were granulated
with the solid raw
material, stored in the refrigerator over night for setting and mixed again.
The resultant blends
were used directly for extrusion. Extrusion was carried out on a small-scale
twin-screw extruder
(rotation speed of 80 rpm) at a temperature of 150 C. The resultant amorphous
solid dispersion
was characterized by DSC and polarized light microscopy (PLM). For in-vitro
dissolution
studies, the release of Compound IB from above amorphous solid dispersion was
evaluated in pH
6.8 phosphate buffer by HPLC assay.
For spray drying, the same composition as applied for melt extrusion was
dissolved in a isopropyl alcohol/water mixture, giving a feed solution
formulation of 2 %
Compound IB, 16.4% copovidone, 1% Lauroglycol FCC, 0.4% Vitamin E TPGS, 0.2%
Aerosil
200, 70% isopropyl alcohol and 10% DI water. The solid dispersion was
manufactured using a
32
CA 02802180 2012-12-10
WO 2011/156578
PCT/US2011/039769
lab-scale spray drier at an inlet temperature of 110 C and a rotavapor for
post-drying at 40 C
and 40 mbar abs. to remove remaining solvents. The spray dried solid
dispersion was tested for
residual solvent content.
The yielded solid dispersions were compressed each into a 100 mg tablet by
applying a direct-blend / direct-compression process of 50% solid dispersion,
28% Avicel 102,
14% Di-CAFOS A, 5% croscarmellose sodium, 1% Aerosil 200 and 2% sodium stearyl
fumarate.
The pharmacokinetic study in dogs showed excellent bioavailability of
Compound IB in the spray dried as well as in the melt extrusion tablet form
compared to in vivo
administration of a reference liquid formulation of compound IB. Compressed
tablets of both
forms exhibited no degradation of compound IB when stored at 40 C and 75% rel.
humidity over
4 weeks. Dissolution behavior as well as the glass transition temperature
remains constant.
Compound IB was also formulated in solid dispersion with other surfactants
such
as Tween 80 or Cremophor RH40.
The foregoing description of the present invention provides illustration and
description, but is not intended to be exhaustive or to limit the invention to
the precise one
disclosed. Modifications and variations are possible in light of the above
teachings or may be
acquired from practice of the invention. Thus, it is noted that the scope of
the invention is
defined by the claims and their equivalents.
33
